By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Molecular Partners AG 

c/o Department of Biochemistry
Winterthurerstrasse 190
Zürich    8057  Switzerland
Phone: 41-44-635-65-00 Fax: 41-44-635-65-07


SEARCH JOBS








Company News
Swiss Biotech Firm Molecular Partners AG Plans $134 Million IPO 9/23/2014 7:05:53 AM
Molecular Partners AG Release: Stage 3 Phase 2 Study Of DARPin Abicipar Pegol (Previously MP0112) Supports Progressing To Phase 3 Development Program 7/1/2014 9:36:24 AM
Roche (RHHBY), Molecular Partners AG Ink $1 Billion+ Cancer Pact 12/4/2013 6:32:39 AM
Molecular Partners AG Announces Publication of Results From a Phase I/II Clinical Trial of Its anti-VEGF DARPin MP0112 in Diabetic Macular Edema 1/17/2013 9:52:15 AM
Allergan Inc. (AGN), Molecular Partners AG Ink $1.5 Billion Exclusive Pact 8/21/2012 6:46:43 AM
Molecular Partners AG Strengthens Management Team With the Appointment of Lisa Rojkjaer, MD as Chief Medical Officer 5/31/2012 10:13:52 AM
Molecular Partners AG Comments on Allergan Inc. (AGN)'s Progress in Phase IIa Retinal Disease Trial Using Anti-VEGF DARPin® 4/5/2012 9:14:07 AM
Johnson & Johnson (JNJ)'s Janssen Biotech Inc. and Molecular Partners AG Expand Agreement to Immunological Diseases in Deal Worth $800 Million 12/8/2011 6:55:49 AM
Swiss Biotech IPOs Including Molecular Partners AG May Revive Health-Care Industry Starved of Investment 7/8/2011 8:28:22 AM
Allergan Inc. (AGN) and Molecular Partners AG Enter Exclusive License Agreement for MP0112; Molecular Partners to Receive $45 Million Upfront and up to $375 Million in Milestone Payments 5/4/2011 8:24:47 AM
12
//-->